JelloX Biotech Inc. is a startup company focusing on open innovation in translating 3D digital pathology imaging with AI-empowered analysis into precision diagnosis solution. Proprietary technologies enable 3D image-inspired AI models to facilitate spatial feature recognition and 3D pathology parameters including recent publication of lung cancer PD-L1 biomarker profiling for 3D TPS evaluation with better concordance to IO drug treatment outcome, and prostate cancer whole lumen morphology for 3D Gleason scoring with rapid process. We have developed perineural invasion AI model for oral cancer, and H&E image-based fluorescence nuclear detection AI model for breast cancer. JelloX 3D + AI solution is compatible with current pathology workflow allowing subsequent H&E, IHC, and genetic tests to establish an innovative Panoramic Pathology Platform in support of multidimensional tumor atlas analyses. Meanwhile, JelloX MetaLite software with CPU-based edge AI solution has become Intel Market Ready Solution for partnership in business development. JelloX digital pathology platform with federated learning (FL) modules is integrated with Roche Diagnostic system as a powerful AI+FL solution for smart hospital and modern reference lab in support of precision medicine and drug development. JelloX Biotech is now seeking for partnership to boost global market penetration and company valuation.
我们正在追踪 JelloX Biotech Inc. 的市场扩张
JelloX Biotech Inc. 的国际扩张与竞争对手的对比情况
JelloX Biotech Inc.你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 JelloX Biotech Inc.你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
JelloX Biotech 揭示人工智能驱动的 3D 数字病理学愿景，与美国主要医疗机构合作，利用先进技术改善癌症患者护理成果。
JelloX生物科技公布AI驱动3D数字病理学愿景，致力于以患者为中心的护理，全球合作改善癌症诊断和治疗结果。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 JelloX Biotech Inc. 的业务、市场和增长信号的快速解答。
